GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Other Stockholders Equity

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Other Stockholders Equity : $-0.00 Mil (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Other Stockholders Equity?

Clinuvel Pharmaceuticals's Other Stockholders Equity for the quarter that ended in Dec. 2023 was $-0.00 Mil.

Clinuvel Pharmaceuticals's quarterly Other Stockholders Equity stayed the same from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil) but then declined from Jun. 2023 ($0.00 Mil) to Dec. 2023 ($-0.00 Mil).

Clinuvel Pharmaceuticals's annual Other Stockholders Equity increased from Jun. 2021 ($-0.00 Mil) to Jun. 2022 ($0.00 Mil) and increased from Jun. 2022 ($0.00 Mil) to Jun. 2023 ($0.00 Mil).


Clinuvel Pharmaceuticals Other Stockholders Equity Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Other Stockholders Equity Chart

Clinuvel Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Clinuvel Pharmaceuticals Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Clinuvel Pharmaceuticals Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity


Clinuvel Pharmaceuticals Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000
Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Headlines

From GuruFocus

PRÉNUMBRA® - CLINUVEL's Second Afamelanotide Formulation

By Marketwired Marketwired 07-13-2020

SCENESSE® to be Prescribed in China

By Marketwired Marketwired 04-23-2020

FDA Approves SCENESSE® For Genetic Disorder

By Marketwired Marketwired 10-09-2019

CLINUVEL delivers second positive financial result

By Marketwired Marketwired 08-29-2018

US FDA Review for SCENESSE® Extended by Three Months

By Marketwired Marketwired 06-03-2019

Positive final results in stroke

By GuruFocusNews GuruFocusNews 05-04-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 07-09-2022

CLINUVEL progresses vitiligo treatment program

By GuruFocusNews GuruFocusNews 06-19-2022

CLINUVEL Opens VALLAURIX R&D Centre In Singapore

By Marketwired Marketwired 08-31-2020